CoChat

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway

Open access
Xiang, Jie, Qin, Liyan, Zhong, Jinling, Xia, Ning, Liang, Yuzhen · 2023 · Diabetes, Metabolic Syndrome and Obesity

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 1 of the 23 sources its claims cite were checked for support.

Abstract

Background: Obesity is related to the loss of skeletal muscle mass and function (sarcopenia). The co-existence of obesity and sarcopenia is called sarcopenic obesity (SO). Glucagon like peptide-1 receptor agonists (GLP-1RA) are widely used in the treatment of diabetes and obesity. However, the protective effects of GLP-1RA on skeletal muscle in obesity and SO are not clear. This study investigated the effects of GLP-1RA liraglutide and semaglutide on obesity-induced muscle atrophy and explored the underlying mechanisms. Methods: Thirty-six male C57BL/6J mice were randomly divided into two groups and fed a regular diet and a high-fat diet for 18 weeks, respectively. After establishing an obesity model, mice were further divided into six groups: control group, liraglutide (LIRA) group, semaglutide (SEMA) group, high-fat diet (HFD) group, HFD + LIRA group, HFD + SEMA group, and subcutaneous injection for 4 weeks. The body weight, muscle mass, muscle strength, glycolipid metabolism, muscle atrophy markers, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed. C2C12 myotube cells treated with palmitic acid (PA) were divided into four groups: control group, PA group, PA + LIRA group, PA + SEMA group. The changes in glucose uptake, myotube diameter, lipid droplet infiltration, markers of muscle atrophy, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed, and the changes in related indicators were observed after the addition of SIRT1 inhibitor EX527. Results: Liraglutide and semaglutide reduced HFD-induced body weight gain, excessive lipid accumulation and improved muscle atrophy. Liraglutide and semaglutide eliminated the increase of muscle atrophy markers in skeletal muscle and C2C12 myotubes. Liraglutide and semaglutide restored impaired glucose tolerance and insulin resistance. However, these beneficial effects were attenuated by inhibiting SIRT1 expression. Conclusion: Liraglutide and semaglutide protects skeletal muscle against obesity-induced muscle atrophy via the SIRT1 pathway.

Overview

CoChat Summary

TL;DR

Liraglutide and semaglutide improved obesity-induced skeletal muscle atrophy, lipid accumulation, and insulin resistance in high-fat-diet mice and palmitic-acid-treated C2C12 myotubes. The protective effects were attenuated by SIRT1 inhibition, supporting a SIRT1-dependent mechanism.

Key findings

  • In HFD-fed mice, liraglutide and semaglutide reduced body weight gain; the Discussion reports HFD mice lost 17.8% of body weight with liraglutide and 20.1% with semaglutide.
  • GLP-1RA treatment improved muscle strength and mass: HFD decreased relative grip strength and limb suspension time, increased body fat/visceral fat, and reduced lean body mass percentage and relative lower-limb muscle weight; liraglutide and semaglutide reversed these changes.
  • Liraglutide and semaglutide improved glucose tolerance, insulin resistance, and dyslipidemia, and reduced muscle atrophy markers while increasing myogenic markers, GLUT4, and SIRT1 in HFD mice.
  • In PA-treated C2C12 myotubes, liraglutide and semaglutide reduced Atrogin-1/MuRF-1, increased MyoD/Myogenin, improved myotube diameter, lipid accumulation, and 2-NBDG glucose uptake; the SIRT1 inhibitor EX-527 attenuated these improvements.

Methods

  • Thirty-six male C57BL/6J mice (8 weeks old, 20.1±1.1 g) were fed a normal diet or HFD (60 kcal% fat) for 18 weeks, then divided into Control, LIRA, SEMA, HFD, HFD+LIRA, and HFD+SEMA groups; liraglutide (400 µg/kg/d) or semaglutide (60 µg/kg/d) was injected subcutaneously for 4 weeks.
  • C2C12 myotubes were differentiated and treated with 1.0 mM palmitic acid (PA) for 24 hours, divided into control, PA, PA+LIRA (400 nM), and PA+SEMA (60 nM) groups; EX-527 (100 µM) was used to inhibit SIRT1.
  • Outcomes included body weight, muscle mass/strength, IPGTT/ITT, biochemical indices, Micro CT, H&E and Oil Red O staining, qRT-PCR, Western blotting, immunofluorescence, and 2-NBDG glucose uptake; statistics used SPSS 23.0 with mean±SD, t-test/ANOVA, and P<0.05 significance.

Limitations

  • The paper does not state a limitations section.
  • Evident from the text: findings are preclinical only, using male C57BL/6J mice and C2C12 myotubes, with no human or female data.
  • Evident from the text: SIRT1 causal evidence relies mainly on the inhibitor EX-527 in vitro, with no in vivo SIRT1 manipulation; the paper also reports HFD body weight excess as 40% in Results but 49% in Discussion.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/dmso.s425642

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Beneficial effects of liraglutide and semaglutide on body weight, muscle strength, and muscle mass in HFD mice. (A) Changes in body size between HFD fed and normal diet fed mice. (B) Dynamic changes in body weight. (C) Changes in body weight after treatment with liraglutide and semaglutide. (D) Changes in relative grip strength. (E) Changes in longest hanging time. (F) Changes in body fat percentage. (G) Changes in visceral fat. (H) Changes in lean body mass percentage. (I) Changes in relative lower limb muscles mass. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.
Figure 1 Beneficial effects of liraglutide and semaglutide on body weight, muscle strength, and muscle mass in HFD mice. (A) Changes in body size between HFD fed and normal diet fed mice. (B) Dynamic changes in body weight. (C) Changes in body weight after treatment with liraglutide and semaglutide. (D) Changes in relative grip strength. (E) Changes in longest hanging time. (F) Changes in body fat percentage. (G) Changes in visceral fat. (H) Changes in lean body mass percentage. (I) Changes in relative lower limb muscles mass. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.CC BY-NC · PubMed Central
Figure 2 Liraglutide and semaglutide significantly improved glucose tolerance, insulin resistance, dyslipidemia, and muscle atrophy in HFD mice. (A) IPGTT was performed for each group. (B) ITT was performed for each group. (C) The levels of HOMA-IR in each group. (D) The levels of TG in each group. (E) The levels of TC in each group. (F) Representative images of GAS muscle H&E staining (scale bar = 50 μm). (G) The mean muscle CSA in each group. (H) Representative images of GAS muscle Oil Red O staining (scale bar = 50 μm). (I) Oil red staining area of each group. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.
Figure 2 Liraglutide and semaglutide significantly improved glucose tolerance, insulin resistance, dyslipidemia, and muscle atrophy in HFD mice. (A) IPGTT was performed for each group. (B) ITT was performed for each group. (C) The levels of HOMA-IR in each group. (D) The levels of TG in each group. (E) The levels of TC in each group. (F) Representative images of GAS muscle H&E staining (scale bar = 50 μm). (G) The mean muscle CSA in each group. (H) Representative images of GAS muscle Oil Red O staining (scale bar = 50 μm). (I) Oil red staining area of each group. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.CC BY-NC · PubMed Central
Figure 3 Liraglutide and semaglutide improved muscle atrophy and insulin resistance in HFD mice through the SIRT1 pathway. (A) The mRNA level of muscle atrophy marker Atrogin-1 was assessed by qRT-PCR. (B) The protein expression of Atrogin-1 was assessed by Western blotting. (C) The mRNA level of myogenic factor Myogenin was assessed by qRT-PCR. (D) The protein expression of Myogenin was assessed by Western blotting. (E) The mRNA level of GLUT4 was assessed by qRT-PCR. (F) The protein expression of GLUT4 was assessed by Western blotting. (G) The mRNA level of SIRT1 was assessed by qRT-PCR. (H) The protein expression of SIRT1 was assessed by Western blotting. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.
Figure 3 Liraglutide and semaglutide improved muscle atrophy and insulin resistance in HFD mice through the SIRT1 pathway. (A) The mRNA level of muscle atrophy marker Atrogin-1 was assessed by qRT-PCR. (B) The protein expression of Atrogin-1 was assessed by Western blotting. (C) The mRNA level of myogenic factor Myogenin was assessed by qRT-PCR. (D) The protein expression of Myogenin was assessed by Western blotting. (E) The mRNA level of GLUT4 was assessed by qRT-PCR. (F) The protein expression of GLUT4 was assessed by Western blotting. (G) The mRNA level of SIRT1 was assessed by qRT-PCR. (H) The protein expression of SIRT1 was assessed by Western blotting. *P < 0.05 compared with the control group, #P < 0.05 compared with the HFD group.CC BY-NC · PubMed Central
Figure 4 Liraglutide and semaglutide alleviated PA induced muscle atrophy, lipid accumulation, and insulin resistance in C2C12 myotubes. (A) The mRNA level of Atrogin-1 was measured by qRT-PCR. (B) The mRNA level of MuRF-1 was measured by qRT-PCR. (C) The mRNA level of MyoD was measured by qRT-PCR. (D) The mRNA level of Myogenin was measured by qRT-PCR. (E) Representative images of MYH2 immunofluorescence in C2C12 myotubes (scale bar = 50 μm). (F) The diameter of myotubes. (G) Representative images of lipid accumulation in C2C12 myotubes stained with oil red O (scale bar = 50 μm). (H) The Oil red staining area. (I) The mRNA level of GLUT4 was measured by qRT-PCR. (J) The fluorescence intensity of 2-NBDG glucose uptake. *P < 0.05 compared with the control group, #P < 0.05 compared with the PA group.
Figure 4 Liraglutide and semaglutide alleviated PA induced muscle atrophy, lipid accumulation, and insulin resistance in C2C12 myotubes. (A) The mRNA level of Atrogin-1 was measured by qRT-PCR. (B) The mRNA level of MuRF-1 was measured by qRT-PCR. (C) The mRNA level of MyoD was measured by qRT-PCR. (D) The mRNA level of Myogenin was measured by qRT-PCR. (E) Representative images of MYH2 immunofluorescence in C2C12 myotubes (scale bar = 50 μm). (F) The diameter of myotubes. (G) Representative images of lipid accumulation in C2C12 myotubes stained with oil red O (scale bar = 50 μm). (H) The Oil red staining area. (I) The mRNA level of GLUT4 was measured by qRT-PCR. (J) The fluorescence intensity of 2-NBDG glucose uptake. *P < 0.05 compared with the control group, #P < 0.05 compared with the PA group.CC BY-NC · PubMed Central
Figure 5 Liraglutide and semaglutide mitigated PA induced muscle atrophy and insulin resistance via the SIRT1 pathway. (A) The mRNA level of SIRT1 was measured by qRT-PCR. (B) The effect of 100 µM EX-527 on inhibiting SIRT-1 protein expression was determined by Western blotting. (C) The protein expression of Atrogin-1 was assessed by Western blotting. (D) The protein expression of Myogenin was assessed by Western blotting. (E)The protein expression of GLUT4 was assessed by Western blotting. (F) The protein expression of SIRT1 was assessed by Western blotting. *P < 0.05 compared with the control group, #P < 0.05 compared with the PA group, &P < 0.05 compared with the PA+LIRA or PA+SEMA group.
Figure 5 Liraglutide and semaglutide mitigated PA induced muscle atrophy and insulin resistance via the SIRT1 pathway. (A) The mRNA level of SIRT1 was measured by qRT-PCR. (B) The effect of 100 µM EX-527 on inhibiting SIRT-1 protein expression was determined by Western blotting. (C) The protein expression of Atrogin-1 was assessed by Western blotting. (D) The protein expression of Myogenin was assessed by Western blotting. (E)The protein expression of GLUT4 was assessed by Western blotting. (F) The protein expression of SIRT1 was assessed by Western blotting. *P < 0.05 compared with the control group, #P < 0.05 compared with the PA group, &P < 0.05 compared with the PA+LIRA or PA+SEMA group.CC BY-NC · PubMed Central
Figure 6 Schematic diagram of beneficial effects of liraglutide and semaglutide on obesity-induced skeletal muscle atrophy.
Figure 6 Schematic diagram of beneficial effects of liraglutide and semaglutide on obesity-induced skeletal muscle atrophy.CC BY-NC · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 16 Not checked · 72 Own results and interpretations

22 references still to check

A free account verifies the references that are still open.

Verify all 22 references — free account
  • Not yet classified. 82
  • It may state two separate claims as one. 2
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 59 references

Cited by

Metadata

Authors
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y.
Affiliations
  • First Affiliated Hospital of GuangXi Medical University (CN)
  • Guangxi Medical University (CN)
Corresponding author
Liang, Yuzhen
Venue
Diabetes, Metabolic Syndrome and Obesity
Published
2023-08
Volume
Volume 16
Pages
2433-2446
ISSN
1178-7007 (ISSN-L)
OpenAlex
W4385840652
Cited by
100
References
59
Citations by year
2026: 30 · 2025: 47 · 2024: 22 · 2023: 1
FWCI
8.91
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Natural Science Foundation of China (8176030057)
  • Natural Science Foundation of Guangxi Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
liraglutide, semaglutide, GLP-1 receptor agonists, sarcopenic obesity, skeletal muscle atrophy, SIRT1, high-fat diet, insulin resistance, glucose tolerance, GLUT4, palmitic acid, C2C12 myotubes, EX527

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.